In this article
Targeting the Circadian Clock for Advanced Brain Tumor Treatment
Treating brain tumor involves high level of expertise and new approach with latest technology & medicines is required to effectively combat this deadly disease. A new study and approach to cancer treatment shows targeting body biological clock. Two compounds that targets the elements of circadian clock destroys several kinds of cancer cells in the laboratory and slowed the growth of brain tumor in mice without having any impact on normal cells.
The Circadian Clock
The circadian clock is a complex natural hardware that controls the every day musicality of human body, for example, rest, body temperature, and assimilation. The ace βclockβ is a zone in the cerebrum that faculties ecological prompts, (for example, light) and conveys data to auxiliary checks in different organs.
Moreover, every cell in the body contains its very own clock that controls the day by day swaying of numerous cell capacities. All checks in the body are for the most part in a state of harmony, enabling the life form to adjust to its condition and keep up a natural equalization.
REV-ERB proteins are key segments of the clock hardware that subdue natural capacities that disease cells rely upon, for example, cell division and cell digestion. So Dr. Panda and his partners chose to explore whether intensifies that actuate REV-ERBs (known as REV-ERB agonists) may probably execute malignant growth cells by blocking capacities they have to keep developing.
In lab tries, the analysts found that two REV-ERB agonists murdered diverse kinds of malignancy cells (counting mind, colon, and bosom), despite the fact that the cells had distinctive hereditary transformations that drive disease development. The REV-ERB agonists did not murder solid mind or skin cells, be that as it may.
These discoveries recommend that medicates that actuate REV-ERBs conceivably could be utilized to treat a wide range of kinds of malignancy, the analysts clarified.
Researchers are creating drugs that initiate or curb other circadian clock parts, and it is conceivable that blends of various clock-focusing on medications or of clock-focusing on medications with different kinds of treatment may improve anticancer impacts. In any case, right now, there are a larger number of inquiries than there are answers.
For brain tumor treatment and surgery connect with us at +91 96 1588 1588. Or email your reports at [email protected] for free consultation.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination β travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
About Sai Sree
β Reviewed for medical accuracy by the CancerFax review panel.
Medical Disclaimer
This article is for educational purposes only and should not replace medical advice, diagnosis, or treatment from a qualified oncology specialist. Every patient's case is different. Treatment decisions should always be made after a review of complete medical records by the treating medical team.
Treatment availability, eligibility, timelines, and access can change. Any clinical trial participation depends on detailed review and approval by the trial hospital or investigator.